Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.
Identifieur interne : 001931 ( PubMed/Corpus ); précédent : 001930; suivant : 001932Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.
Auteurs : Robert E. BurkeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : alpha-Synuclein.
- diagnosis : Parkinsonian Disorders.
- metabolism : Parkinsonian Disorders.
- physiopathology : Parkinsonian Disorders.
- Evaluation Studies as Topic, Humans, Severity of Illness Index.
Abstract
Braak and colleagues have proposed a staging scheme for Parkinson's disease (PD) based on patterns of abnormal immunostaining for alpha-synuclein. They have proposed a temporal sequence in which the appearance of Lewy bodies and neurites in brainstem structures represent the earliest manifestations of the disease, and that this involvement of non-dopaminergic structures long antedates involvement of the substantia nigra and the appearance of the cardinal motor signs that are now required for diagnosis. This proposed scheme has had a wide and profound impact on many aspects of current thinking about PD, and it has already received wide acceptance. Given the importance and growing acceptance of the Braak staging scheme, the Scientific Program Committee for this Educational Symposium to honor the 50th Anniversary of the Parkinson's Disease Foundation agreed that it would be highly worthwhile to devote an entire session of the Scientific Program to consideration of the Braak staging scheme. There was a consensus among members of the Committee that, given the importance of the Braak scheme, it would be of value to create a venue that would stimulate and encourage a thorough and incisive critical analysis.
DOI: 10.1002/mds.22783
PubMed: 20187252
Links to Exploration step
pubmed:20187252Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.</title><author><name sortKey="Burke, Robert E" sort="Burke, Robert E" uniqKey="Burke R" first="Robert E" last="Burke">Robert E. Burke</name><affiliation><nlm:affiliation>Department of Neurology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. rb43@columbia.edu</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.22783</idno><idno type="RBID">pubmed:20187252</idno><idno type="pmid">20187252</idno><idno type="wicri:Area/PubMed/Corpus">001931</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.</title><author><name sortKey="Burke, Robert E" sort="Burke, Robert E" uniqKey="Burke R" first="Robert E" last="Burke">Robert E. Burke</name><affiliation><nlm:affiliation>Department of Neurology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. rb43@columbia.edu</nlm:affiliation></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation Studies as Topic</term><term>Humans</term><term>Parkinsonian Disorders (diagnosis)</term><term>Parkinsonian Disorders (metabolism)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Severity of Illness Index</term><term>alpha-Synuclein (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Evaluation Studies as Topic</term><term>Humans</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Braak and colleagues have proposed a staging scheme for Parkinson's disease (PD) based on patterns of abnormal immunostaining for alpha-synuclein. They have proposed a temporal sequence in which the appearance of Lewy bodies and neurites in brainstem structures represent the earliest manifestations of the disease, and that this involvement of non-dopaminergic structures long antedates involvement of the substantia nigra and the appearance of the cardinal motor signs that are now required for diagnosis. This proposed scheme has had a wide and profound impact on many aspects of current thinking about PD, and it has already received wide acceptance. Given the importance and growing acceptance of the Braak staging scheme, the Scientific Program Committee for this Educational Symposium to honor the 50th Anniversary of the Parkinson's Disease Foundation agreed that it would be highly worthwhile to devote an entire session of the Scientific Program to consideration of the Braak staging scheme. There was a consensus among members of the Committee that, given the importance of the Braak scheme, it would be of value to create a venue that would stimulate and encourage a thorough and incisive critical analysis.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20187252</PMID><DateCreated><Year>2010</Year><Month>03</Month><Day>03</Day></DateCreated><DateCompleted><Year>2010</Year><Month>06</Month><Day>14</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25 Suppl 1</Volume><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.</ArticleTitle><Pagination><MedlinePgn>S76-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22783</ELocationID><Abstract><AbstractText>Braak and colleagues have proposed a staging scheme for Parkinson's disease (PD) based on patterns of abnormal immunostaining for alpha-synuclein. They have proposed a temporal sequence in which the appearance of Lewy bodies and neurites in brainstem structures represent the earliest manifestations of the disease, and that this involvement of non-dopaminergic structures long antedates involvement of the substantia nigra and the appearance of the cardinal motor signs that are now required for diagnosis. This proposed scheme has had a wide and profound impact on many aspects of current thinking about PD, and it has already received wide acceptance. Given the importance and growing acceptance of the Braak staging scheme, the Scientific Program Committee for this Educational Symposium to honor the 50th Anniversary of the Parkinson's Disease Foundation agreed that it would be highly worthwhile to devote an entire session of the Scientific Program to consideration of the Braak staging scheme. There was a consensus among members of the Committee that, given the importance of the Braak scheme, it would be of value to create a venue that would stimulate and encourage a thorough and incisive critical analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. rb43@columbia.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS26836</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS38370</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D005069">Evaluation Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051844">alpha-Synuclein</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22783</ArticleId><ArticleId IdType="pubmed">20187252</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001931 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001931 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20187252
|texte= Evaluation of the Braak staging scheme for Parkinson's disease: introduction to a panel presentation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20187252" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |